Other phencyclidine-induced disorders are described in other chapters of the manual with disorders with which they share phenomenology (see the substance/medication-induced mental disorders in these chapters): phencyclidine-induced psychotic disorder (”Schizo- ders”). For phencyclidine-induced intoxication delirium, see the criteria and discussion of delirium in the chapter ”Neurocognitive Disorders.” These phencyclidine-induced disor- ders are diagnosed instead of phencyclidine intoxication only when the symptoms are suf- ficiently severe to warrant independent clinical attention.
The following other hallucinogen-induced disorders are described in other Chapters of the manual with disorders with which they share phenomenology (see the substance/medi- cation-induced mental disorders in these chapters): other hallucinogen—induced psychotic disorder ("Anxiety Disorders"). For other hallucinogen intoxication delirium, see the cri- teria and discussion of delirium in the chapter "Neurocognitive Disorders.” These hallu— cinogen-induced disorders are diagnosed instead of other hallucinogen intoxication only when the symptoms are sufficiently severe to warrant independent clinical attention.
292.9 (F16.99)
This category applies to presentations in which symptoms characteristic of a phencycli- dine-related disorder that cause clinically significant distress or impairment in social, oc- cupational, or other important areas of functioning predominate but do not meet the full criteria for any specific phencyclidine-related disorder or any of the disorders in the sub- stance-related and addictive disorders diagnostic class.
292.9 (F16.99)
This category applies to presentations in which symptoms characteristic of a hallucinogen- related disorder that cause clinically significant distress or impairment in social, occupa- tional, or other imponant areas of functioning predominate but do not meet the full criteria for any specific hallucinogen-related disorder or any of the disorders in the substance- related and addictive disorders diagnostic class.
A. A problematic pattern of use of a hydrocarbon-based inhalant substance leading to clinically significant impairment or distress, as manifested by at least two of the follow- ing, occurring within a 12-month period: 1. The inhalant substance is often taken in larger amounts or over a longer period than was intended.
2. There is a persistent desire or unsuccessful efforts to cut down or control use of the inhalant substance.
3. A great deal of time is spent in activities necessary to obtain the inhalant substance, use it, or recover from its effects.
4. Craving, or a strong desire or urge to use the inhalant substance.
5. Recurrent use of the inhalant substance resulting in a failure to fulfill major role ob- ligations at work, school, or home.
6. Continued use of the inhalant substance despite having persistent or recurrent so- cial or interpersonal problems caused or exacerbated by the effects of its use.
7. Important social. occupational, or recreational activities are given up or reduced be- cause of use of the inhalant substance.
8. Recurrent use of the inhalant substance in situations in which it is physically haz- ardous.
9. Use of the inhalant substance is continued despite knowledge of having a persis- tent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance.
10. Tolerance, as defined by either of the following: a. A need for markedly increased amounts of the inhalant substance to achieve intoxication or desired effect.
b. A markedly diminished effect with continued use of the same amount of the in- halant substance.
Specify the particular inhalant: When possible, the particular substance involved should be named (e.g., “solvent use disorder”).
Specify it: